AstraZeneca also disclosed it is halting a separate lung cancer treatment trial involving volrustomig in combination with chemotherapy, citing findings that the regimen was unlikely to improve survival compared with another existing therapy. The company said the move followed a planned review of trial data by an independent data monitoring committee.